Browse by Section 100 Item List
Efficient Funding of Chemotherapy – Related Benefits
Further information can be found in the Explanatory Notes.
- Legend
- MPMedical Practitioner
-
SO
Supply OnlyProducts that are in a Supply Only state will be available for dispensing, but not for prescribing. PBS Prescriptions written prior to the Supply Only period are able to be dispensed using either the Supply Only product where available, or an equivalent product as specified on the PBS schedule.
| Prescriber code | Item code | Name, manner of administration and form & strength | Max qty packs |
Max qty units |
No. of repeats |
|---|---|---|---|---|---|
| MP | 2550F | APREPITANTaprepitant 165 mg capsule, 1 | 1 | 1 | 5 |
| MP | 14226R | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 4 |
| MP | 14249Y | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 7 |
| MP | 14250B | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 5 |
| MP | 14255G | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 7 |
| MP | 14268Y | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 7 |
| MP | 14277K | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 3 |
| MP | 14289C | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 3 |
| MP | 14298M | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 5 |
| MP | 14575D | ATEZOLIZUMABatezolizumab 1.875 g/15 mL injection, 15 mL vial | 1 | 1 | 8 |
| MP | 12673B | DARATUMUMABdaratumumab 1.8 g/15 mL injection, 15 mL vial | 1 | 1 | 7 |
| MP | 12682L | DARATUMUMABdaratumumab 1.8 g/15 mL injection, 15 mL vial | 1 | 1 | 5 |
| MP | 12745T | DARATUMUMABdaratumumab 1.8 g/15 mL injection, 15 mL vial | 1 | 1 | 4 |
| MP | 12746W | DARATUMUMABdaratumumab 1.8 g/15 mL injection, 15 mL vial | 1 | 1 | 8 |
| MP | 13201T | DARATUMUMABdaratumumab 1.8 g/15 mL injection, 15 mL vial | 1 | 1 | 15 |
| MP | 13203X | DARATUMUMABdaratumumab 1.8 g/15 mL injection, 15 mL vial | 1 | 1 | 5 |
| MP | 1899Y | FOLINIC ACIDfolinic acid 50 mg/5 mL injection, 10 x 5 mL ampoules | 1 | 10 | 2 |
| MP | 5904R | FOLINIC ACIDfolinic acid 15 mg tablet, 10 | 1 | 10 | 0 |
| MP | 11103J | FOSAPREPITANTfosaprepitant 150 mg injection, 1 vial | 1 | 1 | 5 |
| MP | 13650K | FOSNETUPITANT + PALONOSETRONfosnetupitant 235 mg + palonosetron 250 microgram injection, 1 vial | 1 | 1 | 5 |
| MP | 5899L | GRANISETRONgranisetron 3 mg/3 mL injection, 3 mL ampoule | 1 | 1 | 0 |
| MP | 5898K | GRANISETRONgranisetron 2 mg tablet, 1 | 2 | 2 | 0 |
| MP | 5961R | MESNAmesna 1 g/10 mL injection, 15 x 10 mL ampoules | 1 | 15 | 5 |
| MP | 5960Q | MESNAmesna 400 mg/4 mL injection, 15 x 4 mL ampoules | 1 | 15 | 5 |
| MP | 12925G | MYCOBACTERIUM BOVIS BCG DANISH STRAINMycobacterium bovis BCG Danish strain 30 mg injection, 4 vials | 3 | 3 | 1 |
| MP | 5902P | MYCOBACTERIUM BOVIS BCG TICE STRAINMycobacterium bovis BCG Tice strain 500 million CFU injection, 3 vials | 1 | 3 | 1 |
| MP | 10714X | NETUPITANT + PALONOSETRONnetupitant 300 mg + palonosetron 500 microgram capsule, 1 | 1 | 1 | 5 |
| MP | 5848T | ONDANSETRONondansetron 4 mg/5 mL oral liquid, 50 mL | 1 | 1 | 0 |
| MP | 5857G | ONDANSETRONondansetron 4 mg orally disintegrating tablet, 4 | 1 | 4 | 0 |
| MP | 5858H | ONDANSETRONondansetron 8 mg orally disintegrating tablet, 4 | 1 | 4 | 0 |
| MP | 5967C | ONDANSETRONondansetron 4 mg tablet, 4 | 1 | 4 | 0 |
| MP | 5968D | ONDANSETRONondansetron 8 mg tablet, 4 | 1 | 4 | 0 |
| MP | 5853C | PALONOSETRONpalonosetron 250 microgram/5 mL injection, 5 mL vial | 1 | 1 | 0 |
| MP | 10743K | TRASTUZUMABtrastuzumab 600 mg/5 mL injection, 5 mL vial | 1 | 1 | 3 |
| MP | 10811B | TRASTUZUMABtrastuzumab 600 mg/5 mL injection, 5 mL vial | 1 | 1 | 0 |
| MP | 10817H | TRASTUZUMABtrastuzumab 600 mg/5 mL injection, 5 mL vial | 1 | 1 | 3 |
